Berberine
Berberine is an isoquinoline alkaloid found in several plant genera — Berberis (barberry), Coptis (goldthread), Hydrastis (goldenseal), Mahonia, and Phellodendron. It is sold in the UK as a food supplement, typically as berberine hydrochloride (HCl), commonly 400–500 mg per capsule. There are no authorised UK health claims for berberine. Glycaemic, lipid-lowering, and weight-loss framings — particularly the "natural Ozempic" social media narrative — are not authorised UK claims and have been the subject of Advertising Standards Authority complaints in 2024–2025. Anyone with diabetes, prediabetes, or significant cardiovascular risk should be managed via NHS pathways.
Camden Medicals editorial · Last reviewed 12 June 2026 · Next review December 2026
- Cross-checked against
- NHS
- NICE
- BNF
- EFSA
- FSA
Camden's own editorial team graded each health claim below on the strength of the published evidence — trials weighed with Cochrane RoB 2, systematic reviews with AMSTAR 2, under the CEGA method. See the grade beside every condition.
- Class
- Botanical
- Typical daily dose
- Trials have most commonly used 1500 mg/day, split as 500 mg three times daily with meals. Lower doses (1000 mg/day) feature in some trials. There is no UK consensus dose because there is no UK-authorised claim.
- Top use evidence
- Limited
On this page
What it is
Berberine is a yellow isoquinoline alkaloid extracted from the bark, roots and stems of plants in several genera. The most common commercial sources are Berberis aristata (Indian barberry / tree turmeric), Berberis vulgaris (European barberry), Coptis chinensis (Chinese goldthread), Hydrastis canadensis (goldenseal), and Phellodendron amurense (Amur cork tree). Berberine has a long history of use in traditional Chinese and Ayurvedic medicine and a parallel history of use in herbal medicine in Europe and North America for digestive and inflammatory complaints.
Commercial supplements supply berberine almost exclusively as berberine hydrochloride (HCl) — the more water-soluble salt form — at 400–500 mg per capsule, typically dosed two or three times daily. Berberine bioavailability from oral dosing is modest (well under 1% of the administered dose appears in plasma), reflecting extensive first-pass metabolism, P-glycoprotein efflux from enterocytes, and gut-microbial transformation. Various "enhanced bioavailability" formulations exist (phytosome / dihydroberberine / berberine-piperine combinations) with varying evidence of meaningfully improved plasma exposure.
At a glance
- A plant alkaloid found in barberry, goldenseal, goldthread and related plants. Sold in the UK as berberine hydrochloride.
- No UK-authorised health claims; EFSA evaluation on hold for botanicals.
- NOT a "natural Ozempic" or metformin equivalent: GLP-1 receptor agonists (semaglutide, liraglutide) are Prescription-Only Medicines with very different mechanisms and effect sizes, and the widely-repeated metformin-equivalence claim is unsupported. Talk to your GP about diabetes management.
- Significant drug interactions through CYP3A4 inhibition — discuss with pharmacist before combining with prescribed medicines.
What people use it for
Adults with type 2 diabetes or prediabetes
See your GP. NHS pathways for diabetes and prediabetes (lifestyle, metformin, SGLT2 inhibitors, GLP-1 agonists where indicated, structured education) apply. Berberine is not part of these pathways. Self-supplementing as an alternative to NHS care is not appropriate. [1]
Popular, not provenInsufficientAdults wanting "natural Ozempic" weight loss
Berberine is not a natural equivalent of GLP-1 receptor agonists. Mechanism is different (AMPK vs GLP-1R), trial weight-loss effect sizes are smaller, and the comparison has been the subject of ASA scrutiny in 2024-2025. NHS weight-management pathways apply. [2,2]
Popular, not provenInsufficientAdults exploring lipid management
Some trials report modest LDL and triglyceride reductions with 1–1.5 g/day berberine over 8–12 weeks. Effect sizes are smaller and less reliably replicated than statins or ezetimibe; UK NICE pathways for lipid management apply. [3]
Some evidenceLimitedAdults with diagnosed PCOS exploring metabolic-symptom support
Some trials in PCOS report menstrual-cycle and metabolic-marker changes with berberine. UK NHS pathways for PCOS apply (lifestyle, metformin where indicated, hormonal management). Discuss any supplement with the team managing your PCOS. [4]
Some evidenceLimitedAdults exploring herbal options for occasional digestive complaints
Berberine has traditional use in some digestive contexts. Persistent digestive symptoms need GP assessment, not a supplement.
Some evidenceLimited
How it works
Berberine has multiple proposed cellular targets. The most-cited is activation of AMP-activated protein kinase (AMPK), a metabolic-sensing enzyme also activated by metformin and exercise. Through AMPK and parallel pathways, berberine has been reported in laboratory and animal studies to reduce hepatic glucose production, improve insulin sensitivity in adipose and muscle tissue, modulate intestinal glucose absorption, and reduce LDL receptor degradation in hepatocytes. Berberine also has direct effects on the gut microbiome that may contribute to its metabolic profile.
Mechanistic similarity to metformin is a real point in the laboratory literature. Mechanistic similarity is not the same as clinical equivalence: trial effect sizes, dose-response, head-to-head comparisons, and the regulatory framework (metformin is a licensed POM with decades of outcome data) are not on the same footing.
Common myths
Myth""Berberine is nature's Ozempic""
RealityIt is not. GLP-1 receptor agonists (semaglutide / Ozempic / Wegovy / liraglutide) are Prescription-Only Medicines with a different mechanism, dose-response, and trial effect sizes. The framing has been spread on social media and is not supported by comparable trial data. UK ASA has investigated supplement marketing using this comparison. [2]
Myth"Berberine is "natural metformin" with no side effects"
RealityBerberine and metformin share AMPK activation as one mechanistic feature, which is not the same as clinical equivalence. Berberine has its own side-effect profile (dose-dependent diarrhoea is common at 1500 mg/day), bioavailability concerns, and CYP3A4 drug interactions. Naturalness is not a clinical reasoning standard.
Myth"Higher dose berberine = better metabolic effect"
RealityTrials at 1–1.5 g/day are the most-studied. Higher daily doses increase the rate of GI side effects (diarrhoea, nausea, cramping) without strong evidence of additive metabolic benefit. Splitting the daily dose is partly to manage poor bioavailability and partly to manage tolerability.
Myth"Goldenseal supplements are an alternative to berberine"
RealityGoldenseal (Hydrastis canadensis) does contain berberine but also other alkaloids (hydrastine), and the berberine content of commercial goldenseal preparations varies widely. Berberine-HCl supplements deliver a more standardised berberine dose. They are not regulatory equivalents and the clinical literature is largely on isolated berberine, not on goldenseal extracts.
Common online questions
Synthesised from the questions UK shoppers most often ask online about Berberine. Each answer is editorial and links to its evidence in the Sources list below.
Is berberine "nature's Ozempic"?
No. Ozempic (semaglutide) and Wegovy are GLP-1 receptor agonists — Prescription-Only Medicines with very different mechanism, dose-response, and clinical effect sizes than berberine. Berberine acts primarily through AMPK; GLP-1 agonists act on the GLP-1 receptor. Trial weight-loss effect sizes are not comparable. The "natural Ozempic" framing has been spread on social media and has been the subject of UK ASA complaints and rulings in 2024-2025. Talk to your GP about weight-management pathways. [2,6]
Is berberine the same as metformin?
No. Berberine and metformin both activate AMPK as one part of their mechanism, which is the basis for the comparison in laboratory literature. They are not clinically interchangeable. Metformin is a licensed UK POM with decades of outcome data, standardised dosing, and prescribing protocols. Berberine is a food supplement with no UK-authorised health claim. Self- substituting berberine for prescribed metformin is not appropriate and should not be done without speaking to your prescribing team. [5]
I've seen 500 mg three times daily — is that the right dose?
The 1500 mg/day total (500 mg × 3) is the most-studied dose in glycaemic and lipid trials. Bioavailability is poor and the thrice-daily schedule is partly to manage that. There is no UK-authorised dose because there is no UK-authorised health claim. GI complaints (diarrhoea, abdominal pain) are dose-dependent and common at 1500 mg/day.
Will berberine interact with my prescribed medicines?
Likely yes for several drug classes. Berberine inhibits CYP3A4 (the main enzyme that metabolises many prescribed medicines) and is a P-glycoprotein substrate. Notable interactions: cyclosporine plasma levels rise, statin metabolism may slow, sedatives and many antihypertensives can be affected. Talk to your pharmacist before combining berberine with any prescribed medicine — especially if you are on a regime where dose stability matters.
Can I take berberine in pregnancy?
No. Berberine has been associated with displacement of bilirubin from albumin in laboratory studies and has been linked to kernicterus risk in infants exposed in late pregnancy. Berberine crosses the placenta and into breast milk. Avoid in pregnancy and breastfeeding.
⚖️ The official position
What may lawfully be claimed about Berberine in Great Britain. This is a regulatory position, not an evidence grade.
No health claim is authorised for Berberine in Great Britain.
This page describes the evidence and online discussion without making a claim.
UK regulatory landscape
UK regulatory tier: Food supplement
EFSA claim status
EFSA's evaluation of botanical health claims (including berberine claims relating to glycaemic control, lipids, weight, and metabolic syndrome) was paused in 2010 and remains on hold. Pending claims may be referenced as "on hold" but must not be presented as authorised.
UK regulatory rules evolve. This summary is editorial — businesses should consult regulatory counsel; consumers should consult their pharmacist or GP.
🩺 What the guidance says
What UK and international health bodies say. Guidance leads; Camden’s own evidence review follows below.
NHSNot assessed
Type 2 diabetes
The NHS type 2 diabetes pages describe management through diet, physical activity, weight management and prescribed medicines such as metformin, with structured education and regular review. Berberine is not mentioned and is not part of the NHS pathway; people with diabetes or prediabetes are directed to their GP or diabetes team rather than to a supplement.
NHSNot assessed
High cholesterol
The NHS high cholesterol pages describe lowering cholesterol through diet and physical activity, with prescribed medicines such as statins where needed. Berberine and other supplements are not listed among the measures the NHS describes for a raised cholesterol.
NHSNot assessed
Polycystic ovary syndrome
The NHS PCOS pages describe managing symptoms through weight management, a balanced diet and prescribed medicines where appropriate. Berberine is not mentioned; anyone managing PCOS is directed to the team overseeing their care before adding a supplement.
NHSNot assessed
Overweight and obesity in adults
The NHS overweight and obesity pages describe weight management through diet, physical activity and, where prescribed, medicines such as semaglutide, tirzepatide, liraglutide or orlistat given alongside diet and lifestyle support. These medicines are prescribed within NHS services; berberine is not part of this pathway and is not an equivalent of them.
NICENot assessed
Type 2 diabetes in adults: management
NICE's type 2 diabetes guideline sets out the management pathway — education, dietary advice, cardiovascular risk management, and a stepwise approach to glucose-lowering medicines starting with metformin. It does not include berberine among the recommended options.
NICENot assessed
Cardiovascular disease: risk assessment and reduction, including lipid modification
NICE's cardiovascular guideline sets out how cardiovascular risk is assessed and reduced through lifestyle measures and lipid-lowering medicines such as statins. It does not list berberine as a way to lower cholesterol or to reduce cardiovascular risk.
SOCIETY-OTHERConditional
Diabetes UK — Herbal and food supplements
Diabetes UK advises that herbal and food supplements should not be a substitute for prescribed diabetes medicines, that many such products are not regulated in the same way as medicines, and that "natural", "herbal" or "plant-derived" does not mean safe. It directs anyone using supplements to tell their healthcare team and to keep taking their prescribed medication.
EFSANot assessed
EFSA health claims (Article 13) — botanical substances on hold
The European Commission paused the assessment of health claims for botanical substances in 2010, and EFSA has not evaluated them since. Berberine claims relating to blood glucose, lipids, weight and metabolic health fall in this on-hold set: they have not been scientifically assessed and cannot be presented as authorised.
GB-NHCNot assessed
Great Britain Nutrition and Health Claims (NHC) register
The GB Nutrition and Health Claims register lists the health claims authorised for use in Great Britain. It contains no authorised claim for berberine, so no health benefit may lawfully be claimed for it on a UK label, website or advertisement.
SOCIETY-OTHERRecommends against
ASA/CAP advice — Weight control: Prescription-only medicines
UK advertising rules prohibit promoting prescription-only weight-loss medicines to the public and bar a food supplement from being presented as having the same effect. The Advertising Standards Authority has upheld complaints against berberine supplements marketed as a "natural GLP-1" alternative — for example a ruling published on 6 August 2025 — finding that GLP-1 comparison claims are unauthorised medicinal claims.
🔬 Camden’s evidence review
The research Camden reviewed, graded on its strength. This is our own appraisal — it sits beneath the official guidance above, never above it.
Type 2 diabetes glycaemic control
EvidencelimitedMultiple small RCTs and meta-analyses report HbA1c and fasting glucose reductions with berberine (typically 1–1.5 g/day) over 8–12 weeks. Effect sizes are modest and the trial base is dominated by Chinese-population studies of variable quality. Trials directly comparing berberine to first-line UK diabetes therapies at scale are limited. Berberine is not part of NHS or NICE diabetes management.
Lipid profile (LDL, triglycerides)
EvidencelimitedTrials report small-to-moderate LDL and triglyceride reductions at 1–1.5 g/day for 8–12 weeks. Effect sizes are smaller than established statin therapy. NICE lipid-management pathways do not list berberine.
PCOS — insulin resistance and menstrual outcomes
EvidencelimitedSeveral small trials in women with PCOS report improvements in insulin sensitivity markers and menstrual cycles with berberine. Trial sizes are modest and the comparison standard (metformin) has different prescribing context. UK NHS pathways for PCOS apply.
Weight loss / GLP-1-style metabolic effects
EvidenceinsufficientBerberine trials sometimes report modest weight reductions (1–3 kg over 12 weeks). This is a meaningfully smaller effect size than GLP-1 receptor agonists in licensed weight-management indications. The "natural Ozempic" framing is not supported by comparable trial data and is not a UK-authorised claim. [2]
Safety
Berberine has dose-dependent GI side effects (diarrhoea, cramping) at clinical doses, multiple drug interactions through CYP3A4 inhibition, and should be avoided in pregnancy and breastfeeding. It is not a substitute for prescribed diabetes or weight-management treatment.
Talk to your pharmacist or GP first if you:
- You take any prescribed medication metabolised by CYP3A4 (most statins, calcium channel blockers, sedatives, immunosuppressants — talk to your pharmacist with your medication list).
- You take cyclosporine, tacrolimus, or another transplant immunosuppressant — significant interaction risk.
- You take warfarin or DOACs — disclose use.
- You take prescribed diabetes medication (metformin, gliclazide, insulin, GLP-1 agonists, SGLT2 inhibitors) — combination risks hypoglycaemia.
- You have liver or kidney disease.
- You are pregnant, breastfeeding, or trying to conceive — AVOID.
- You are giving any supplement to a child — berberine is not appropriate for infants or children.
Common side effects: GI complaints — diarrhoea, abdominal pain, cramping, nausea, constipation — common at 1500 mg/day; dose-dependent. Headache and rash less common.
Pregnancy and breastfeeding
Berberine should NOT be taken in pregnancy. It crosses the placenta, displaces bilirubin from albumin in laboratory studies, and has been linked to kernicterus risk in infants exposed in late pregnancy. Avoid.
Berberine passes into breast milk and carries kernicterus risk for the infant. Avoid.
Talk to your GP, midwife, or pharmacist before starting any supplement during pregnancy or breastfeeding.
More clinical detail (for clinicians and informed readers)
Contraindications
- Pregnancy and breastfeeding — risk to neonate (bilirubin displacement, kernicterus).
- Infants and young children.
- Active liver disease — discuss with GP.
- Known hypersensitivity to berberine or supplement constituents.
Drug interactions
- CYP3A4 inhibition — affects metabolism of many prescribed medicines (most statins, calcium-channel blockers, several sedatives and immunosuppressants).
- Cyclosporine, tacrolimus — plasma levels can rise meaningfully.
- Diabetes medications — additive hypoglycaemia risk.
- Antihypertensives — possible additive blood-pressure lowering.
- Anticoagulants — disclose use; theoretical additive effects.
This is not an exhaustive list. Always tell your prescriber and pharmacist about every supplement you take.
Common side effects
- GI complaints — diarrhoea, abdominal cramping, nausea, constipation; dose-related.
- Mild headache.
Rare side effects
- Hepatic adverse reactions — case reports.
- Skin rash / allergic reactions.
- Hypoglycaemia when combined with diabetes medication.
How to take it
- Typical supplemental range
- Trials have most commonly used 1500 mg/day, split as 500 mg three times daily with meals. Lower doses (1000 mg/day) feature in some trials. There is no UK consensus dose because there is no UK-authorised claim.
- Timing
- Doses split with meals — partly to manage poor bioavailability, partly to manage GI tolerability.
How to spot quality
Look for
- Berberine hydrochloride (HCl) named explicitly as the form.
- mg per capsule stated clearly; total daily dose calculable.
- Plant source declared (Berberis aristata is the most common commercial source).
- GMP-certified manufacture; ideally heavy-metal and microbial-screen results available on request (alkaloid extraction quality varies by source).
- No anti-diabetes / anti-Ozempic / weight-loss claims on the label.
Red flags
- Marketing as "nature's Ozempic", "natural metformin", "diabetes solution" — none are UK-authorised claims and these framings have been ASA-flagged.
- No mg-per-capsule declaration or vague "berberine complex" wording.
- No plant source named.
- Combination products that bury berberine dose in a "metabolic blend".
- Targeting people with diagnosed diabetes or PCOS without prominent "talk to your prescriber" warnings.
- Pregnancy / breastfeeding "safe to take" claims.
Commonly combined with
Other ingredients that share a biological pathway, cofactor relationship, or evidence-backed protocol with this one. Mechanisms below cite primary physiology — not folk pairing. Doses are literature ranges, not recommendations. Talk to your pharmacist or GP before changing your stack, especially if you take prescription medication.
Milk Thistle (Silybum marianum)
Limited evidenceHepatic-cluster pairing — berberine modulates AMPK + lipid metabolism; silymarin hepatocyte antioxidant + membrane stabilisation.
Berberine AMPK activation + intestinal glucose absorption modulation; milk thistle silymarin hepatocyte antioxidant. Mechanism complementary on hepatic + metabolic axes.
Evidence: Camden milk-thistle + berberine cluster.
Doses studied: 500-1500 mg berberine + 200-600 mg silymarin daily.
Beta-Glucan (β-glucan)
Limited evidenceCardiovascular cluster — berberine + oat β-glucan cholesterol-maintenance combination.
Berberine LDL-receptor up-regulation + AMPK; oat β-glucan bile-acid sequestration. Mechanism complementary on cholesterol axis.
Evidence: Camden beta-glucan UK Article 13.1 / Article 14 cholesterol claims.
Doses studied: 500-1500 mg berberine + ≥3 g/day oat β-glucan.
Vitamin D3
Limited evidenceMetabolic cluster — berberine insulin-sensitisation + vitamin D3 immune / metabolic adjacent.
Different mechanisms; metabolic-marker context.
Evidence: Camden vitamin-d3 NB-476 / NB-537 cluster. [7]
Doses studied: 500-1500 mg berberine + 10-25 µg vitamin D3 daily.
Found in Camden: Weekly Vitamin D3 3000IU + K2 MK-7 90 Capsules · Aurifera® Shilajit Adaptogen Complex 90 Capsules
Sources
Numbered references cited above plus general authoritative reading. Citations in the body link to the matching number here.
How to read these sources:
- Tier 1 (UK authoritative): NHS, NICE, BNF, EFSA, FSA, GB NHC Register, SACN, MHRA.
- Tier 2 (primary literature): peer-reviewed RCTs cited by PMID.
- Tier 3 (mechanistic): in-vitro / animal-model literature — interpret with caveat.